TL;DR
This study reveals that the normal physiological adaptation to pregnancy involves a significant increase in the renin-angiotensin-aldosterone system (RAAS) activity, particularly in aldosterone levels. In contrast, pregnancies that develop hypertension show a stalled or waning activation of the RAAS, with significantly lower aldosterone concentrations in the third trimester, suggesting a key role for RAAS dysregulation in pregnancy hypertension.
What Problem Does This Paper Address?
Pregnancy hypertension, including gestational hypertension and pre-eclampsia, affects a significant portion of pregnancies and carries serious risks for both mother and child. While the renin-angiotensin-aldosterone system (RAAS) is known to be crucial for regulating blood pressure and fluid balance, and its activation is a normal part of pregnancy, the precise mechanisms underlying pregnancy hypertension remain unclear. Specifically, how the RAAS functions differently in pregnancies that develop hypertension compared to those that remain normotensive throughout gestation has not been comprehensively characterized. This study aims to fill this gap by providing a detailed, longitudinal profile of RAAS components in pregnant women, differentiating between those who develop hypertension and those who do not.
Methods
The researchers employed a novel technique called RAS Fingerprint™, a liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based methodology. This method allows for the simultaneous quantification of multiple components of the RAAS, including various angiotensin peptides and aldosterone, from a single blood sample. This approach is considered a gold standard for biological molecule quantification and offers a more comprehensive "snapshot" of RAAS activity compared to traditional methods. The study also calculated derived biomarkers:
- PRA-S (Plasma Renin Activity Surrogate): Calculated as the sum of Angiotensin I and Ang II concentrations.
- ACE-S (ACE Activity Surrogate): Calculated as the ratio of Ang II to Ang I concentrations.
- AA2-R (Aldosterone to Ang II Ratio): Calculated by dividing aldosterone concentration by Ang II concentration.
These biomarkers were measured in the first and third trimesters of pregnancy.
Datasets
The study utilized a cohort of 74 pregnant women recruited from a high-risk maternal-fetal medicine clinic at the University of Kentucky. These women were followed prospectively. The cohort was divided into two groups:
- Normotensive (NT) group: 47 women who remained normotensive throughout pregnancy.
- Hypertensive (HYP) group: 27 women who developed either gestational hypertension or pre-eclampsia after 20 weeks of gestation.
Clinical data and maternal blood samples were collected at two time points: the first trimester (11-16 weeks) and the third trimester (28-32 weeks).
Key Insights and Ideas
- RAAS as a Pregnancy Adaptation: The study strongly supports the idea that a robust activation of the RAAS, particularly an increase in aldosterone, is a critical physiological adaptation for a healthy, normotensive pregnancy. This adaptation is essential for managing the significant increase in blood volume.
- Hypertension as RAAS Stagnation: The most striking insight is that pregnancies destined to develop hypertension exhibit a "stalled" or "waning" activation of the RAAS in the latter half of pregnancy. This is characterized by a lack of significant change in key RAAS components, unlike the progressive increase seen in normotensive pregnancies.
- Aldosterone's Crucial Role: The significantly lower aldosterone levels in the third trimester of hypertensive pregnancies, compared to normotensive ones, highlights aldosterone's critical role in maintaining blood pressure homeostasis during pregnancy. Its attenuated secretion in HYP pregnancies is a key feature of the disorder.
- Angiotensin Peptide Stability: The observation that angiotensin peptide levels remained largely unchanged over gestation in the hypertensive group, while increasing in the normotensive group, suggests a failure in the normal RAAS cascade progression.
Key Results
- Normotensive Pregnancies: In the NT group, PRA-S and aldosterone concentrations significantly increased from the first to the third trimester (PRA-S by ~31%, aldosterone by ~135%). Angiotensin peptide metabolites also showed modest increases.
- Hypertensive Pregnancies: In the HYP group, PRA-S showed no significant increase over gestation (median change of 0%). Aldosterone also increased, but by a smaller percentage (~57%) and this increase was not statistically significant. Crucially, third-trimester aldosterone concentrations were significantly lower in the HYP group compared to the NT group.
- Angiotensin Peptides: While Ang I showed a modest increase in the HYP group (particularly in those with gestational hypertension), Ang II and its metabolites showed little to no significant change over gestation in the HYP group, contrasting with the increases seen in the NT group.
- ACE-S and AA2-R: ACE-S showed a decrease over gestation in both groups, and the Aldosterone-Ang II ratio (AA2-R) increased significantly over gestation in NT patients but not in HYP patients.
Limitations and Future Work
- No Non-Pregnant Control: The study did not include a non-pregnant control group, making direct comparisons to the non-pregnant state impossible. However, the authors note that their RAAS biomarker values in the third trimester of the HYP group were still higher than those reported for hypertensive non-pregnant individuals, suggesting RAAS activity was not completely suppressed.
- Subtype Differentiation: While a subanalysis was performed, the study did not fully differentiate between gestational hypertension and pre-eclampsia due to small numbers. However, the observed RAAS suppression trend was similar in both, being more pronounced in pre-eclampsia.
- Sodium and Volume Status: The study did not control for sodium or volume status, which can influence aldosterone and PRA-S levels. Future research could incorporate these factors.
- Postpartum Measurements: The study did not include postpartum RAAS measurements, which could provide insights into the recovery or persistence of RAAS alterations.
- Tissue Source: The study measured systemic angiotensin peptides, and the specific contribution of local RAAS activity in organs like the placenta and kidneys was not directly assessed, though it is discussed as a potential area of dysregulation.
Future work could focus on understanding the specific molecular mechanisms driving the attenuated RAAS activation in hypertensive pregnancies and exploring how this knowledge can inform early detection or therapeutic strategies for pregnancy hypertension.
Summary updated